(lp0
(dp1
S'contVal'
p2
NsS'drug2'
p3
S'http://bio2rdf.org/drugbank:DB01016'
p4
sS'drug1'
p5
S'http://bio2rdf.org/drugbank:DB00459'
p6
sS'objectUri'
p7
NsS'evidence'
p8
NsS'ddiPkMechanism'
p9
NsS'whoAnnotated'
p10
NsS'contraindication'
p11
NsS'researchStatementLabel'
p12
NsS'severity'
p13
NsS'label'
p14
NsS'effectConcept'
p15
NsS'source'
p16
S'DDI-Corpus-2011'
p17
sS'ddiPkEffect'
p18
NsS'evidenceType'
p19
NsS'homepage'
p20
NsS'pathway'
p21
NsS'ddiType'
p22
NsS'researchStatement'
p23
NsS'dateAnnotated'
p24
NsS'object'
p25
S'\xef\xbb\xbfACITRETIN'
p26
sS'evidenceSource'
p27
NsS'evidenceStatement'
p28
S'Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| \r'
p29
sS'precipUri'
p30
NsS'certainty'
p31
NsS'uri'
p32
NsS'precip'
p33
NsS'numericVal'
p34
NsS'precaution'
p35
NsS'precipitant'
p36
S'Glibenclamide'
p37
sa(dp38
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01159'
p39
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p40
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Adrenaline'
p41
sg27
Nsg28
S'Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| \r'
p42
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fluothane'
p43
sa(dp44
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01001'
p45
sg5
S'http://bio2rdf.org/drugbank:DB01001'
p46
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Albuterol'
p47
sg27
Nsg28
S'Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| \r'
p48
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Albuterol'
p49
sa(dp50
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p51
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p52
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Alcohol'
p53
sg27
Nsg28
S'As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| \r'
p54
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Abilify'
p55
sa(dp56
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p57
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p58
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Alcohol'
p59
sg27
Nsg28
S'Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| \r'
p60
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p61
sa(dp62
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01205'
p63
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p64
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Alcohol'
p65
sg27
Nsg28
S'Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.| \r'
p66
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Romazicon'
p67
sa(dp68
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p69
sg5
S'http://bio2rdf.org/drugbank:DB00898'
p70
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Alcohol'
p71
sg27
Nsg28
S'The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| \r'
p72
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Wellbutrin'
p73
sa(dp74
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p75
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p76
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p77
sg27
Nsg28
S'The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| \r'
p78
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p79
sa(dp80
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00672'
p81
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p82
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p83
sg27
Nsg28
S'The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| \r'
p84
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORPROPAMIDE'
p85
sa(dp86
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00266'
p87
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p88
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p89
sg27
Nsg28
S'The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.| \r'
p90
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dicumarol'
p91
sa(dp92
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p93
sg5
S'http://bio2rdf.org/drugbank:DB00437'
p94
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALLOPURINOL'
p95
sg27
Nsg28
S'Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| \r'
p96
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p97
sa(dp98
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p99
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p100
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALMOTRIPTAN'
p101
sg27
Nsg28
S'Ketoconazole and Other Potent CYP3A4 Inhibitors Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| \r'
p102
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p103
sa(dp104
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p105
sg5
S'http://bio2rdf.org/drugbank:DB00918'
p106
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALMOTRIPTAN'
p107
sg27
Nsg28
S'Verapamil Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| \r'
p108
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p109
sa(dp110
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p111
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p112
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p113
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p114
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p115
sa(dp116
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p117
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p118
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p119
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p120
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p121
sa(dp122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p123
sg5
S'http://bio2rdf.org/drugbank:DB00404'
p124
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALPRAZOLAM'
p125
sg27
Nsg28
S'Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p126
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p127
sa(dp128
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p129
sg5
S'http://bio2rdf.org/drugbank:DB06723'
p130
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ALUMINUM HYDROXIDE'
p131
sg27
Nsg28
S'Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| \r'
p132
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p133
sa(dp134
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00036'
p135
sg5
S'http://bio2rdf.org/drugbank:DB00513'
p136
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMINOCAPROIC ACID'
p137
sg27
Nsg28
S'Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.| \r'
p138
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NovoSeven'
p139
sa(dp140
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p141
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p142
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMIODARONE'
p143
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p144
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p145
sa(dp146
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p147
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p148
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMIODARONE'
p149
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p150
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p151
sa(dp152
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p153
sg5
S'http://bio2rdf.org/drugbank:DB00543'
p154
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMOXAPINE'
p155
sg27
Nsg28
S'Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants.| \r'
p156
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p157
sa(dp158
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00741'
p159
sg5
S'http://bio2rdf.org/drugbank:DB00681'
p160
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMPHOTERICIN B'
p161
sg27
Nsg28
S'In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| \r'
p162
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDROCORTISONE'
p163
sa(dp164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p165
sg5
S'http://bio2rdf.org/drugbank:DB00415'
p166
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMPICILLIN'
p167
sg27
Nsg28
S'Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| \r'
p168
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p169
sa(dp170
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p171
sg5
S'http://bio2rdf.org/drugbank:DB00701'
p172
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AMPRENAVIR'
p173
sg27
Nsg28
S'Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| \r'
p174
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p175
sa(dp176
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p177
sg5
S'http://bio2rdf.org/drugbank:DB01242'
p178
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Anafranil'
p179
sg27
Nsg28
S'Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| \r'
p180
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p181
sa(dp182
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p183
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p184
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ANAGRELIDE'
p185
sg27
Nsg28
S'Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| \r'
p186
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p187
sa(dp188
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB02527'
p189
sg5
S'http://bio2rdf.org/drugbank:DB00261'
p190
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ANAGRELIDE'
p191
sg27
Nsg28
S'Anagrelide is an inhibitor of cyclic AMP PDE III.| \r'
p192
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cyclic AMP'
p193
sa(dp194
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p195
sg5
S'http://bio2rdf.org/drugbank:DB01217'
p196
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ANASTROZOLE'
p197
sg27
Nsg28
S'Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| \r'
p198
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tamoxifen'
p199
sa(dp200
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p201
sg5
S'http://bio2rdf.org/drugbank:DB01213'
p202
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Antizol'
p203
sg27
Nsg28
S'Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| \r'
p204
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p205
sa(dp206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00969'
p207
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p208
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APOMORPHINE'
p209
sg27
Nsg28
S'5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p210
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALOSETRON'
p211
sa(dp212
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00757'
p213
sg5
S'http://bio2rdf.org/drugbank:DB00714'
p214
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APOMORPHINE'
p215
sg27
Nsg28
S'5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| \r'
p216
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dolasetron'
p217
sa(dp218
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p219
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p220
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p221
sg27
Nsg28
S'Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| \r'
p222
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p223
sa(dp224
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p225
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p226
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p227
sg27
Nsg28
S'Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| \r'
p228
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p229
sa(dp230
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00683'
p231
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p232
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p233
sg27
Nsg28
S'Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| \r'
p234
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MIDAZOLAM'
p235
sa(dp236
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p237
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p238
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p239
sg27
Nsg28
S'Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| \r'
p240
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p241
sa(dp242
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p243
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p244
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p245
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p246
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p247
sa(dp248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p249
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p250
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p251
sg27
Nsg28
S'Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| \r'
p252
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p253
sa(dp254
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p255
sg5
S'http://bio2rdf.org/drugbank:DB00673'
p256
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'APREPITANT'
p257
sg27
Nsg28
S'Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| \r'
p258
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p259
sa(dp260
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p261
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p262
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p263
sg27
Nsg28
S'However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| \r'
p264
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Celebrex'
p265
sa(dp266
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p267
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p268
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p269
sg27
Nsg28
S'The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| \r'
p270
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fenoprofen'
p271
sa(dp272
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p273
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p274
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p275
sg27
Nsg28
S'Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| \r'
p276
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nalfon'
p277
sa(dp278
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00627'
p279
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p280
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p281
sg27
Nsg28
S'Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| \r'
p282
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nicotinic Acid'
p283
sa(dp284
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00585'
p285
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p286
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p287
sg27
Nsg28
S'In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| \r'
p288
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nizatidine'
p289
sa(dp290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p291
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p292
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p293
sg27
Nsg28
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p294
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p295
sa(dp296
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p297
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p298
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p299
sg27
Nsg28
S'Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| \r'
p300
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p301
sa(dp302
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p303
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p304
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p305
sg27
Nsg28
S'Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| \r'
p306
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p307
sa(dp308
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00533'
p309
sg5
S'http://bio2rdf.org/drugbank:DB00945'
p310
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Aspirin'
p311
sg27
Nsg28
S'Aspirin Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| \r'
p312
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Vioxx'
p313
sa(dp314
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p315
sg5
S'http://bio2rdf.org/drugbank:DB00637'
p316
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ASTEMIZOLE'
p317
sg27
Nsg28
S'Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p318
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p319
sa(dp320
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01124'
p321
sg5
S'http://bio2rdf.org/drugbank:DB00636'
p322
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Atromid-S'
p323
sg27
Nsg28
S'Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| \r'
p324
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLBUTAMIDE'
p325
sa(dp326
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00859'
p327
sg5
S'http://bio2rdf.org/drugbank:DB00995'
p328
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'AURANOFIN'
p329
sg27
Nsg28
S'Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| \r'
p330
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cuprimine'
p331
sa(dp332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01435'
p333
sg5
S'http://bio2rdf.org/drugbank:DB00068'
p334
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Betaseron'
p335
sg27
Nsg28
S'Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| \r'
p336
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANTIPYRINE'
p337
sa(dp338
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p339
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p340
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BEXAROTENE'
p341
sg27
Nsg28
S'Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p342
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEMFIBROZIL'
p343
sa(dp344
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB04665'
p345
sg5
S'http://bio2rdf.org/drugbank:DB01393'
p346
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Bezalip'
p347
sg27
Nsg28
S'When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.| \r'
p348
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'COUMARIN'
p349
sa(dp350
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00467'
p351
sg5
S'http://bio2rdf.org/drugbank:DB01294'
p352
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BISMUTH SUBSALICYLATE'
p353
sg27
Nsg28
S'Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| \r'
p354
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ENOXACIN'
p355
sa(dp356
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p357
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p358
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p359
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p360
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p361
sa(dp362
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00668'
p363
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p364
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p365
sg27
Nsg28
S'Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| \r'
p366
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EPINEPHRINE'
p367
sa(dp368
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p369
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p370
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p371
sg27
Nsg28
S'Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| \r'
p372
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p373
sa(dp374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p375
sg5
S'http://bio2rdf.org/drugbank:DB00187'
p376
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Brevibloc'
p377
sg27
Nsg28
S'Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| \r'
p378
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p379
sa(dp380
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p381
sg5
S'http://bio2rdf.org/drugbank:DB00921'
p382
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUPRENORPHINE'
p383
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p384
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p385
sa(dp386
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00921'
p387
sg5
S'http://bio2rdf.org/drugbank:DB00921'
p388
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUPRENORPHINE'
p389
sg27
Nsg28
S'In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.| \r'
p390
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Subutex'
p391
sa(dp392
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p393
sg5
S'http://bio2rdf.org/drugbank:DB00490'
p394
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUSPIRONE'
p395
sg27
Nsg28
S'In vitro, buspirone may displace less firmly bound drugs like digoxin.| \r'
p396
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p397
sa(dp398
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01008'
p399
sg5
S'http://bio2rdf.org/drugbank:DB01008'
p400
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUSULFAN'
p401
sg27
Nsg28
S'Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.| \r'
p402
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Busulfex'
p403
sa(dp404
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p405
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p406
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUTORPHANOL'
p407
sg27
Nsg28
S'Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| \r'
p408
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p409
sa(dp410
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p411
sg5
S'http://bio2rdf.org/drugbank:DB00611'
p412
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'BUTORPHANOL'
p413
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p414
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p415
sa(dp416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p417
sg5
S'http://bio2rdf.org/drugbank:DB00136'
p418
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CALCITRIOL'
p419
sg27
Nsg28
S'Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.| \r'
p420
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rocaltrol'
p421
sa(dp422
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p423
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p424
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Celebrex'
p425
sg27
Nsg28
S'CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| \r'
p426
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p427
sa(dp428
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p429
sg5
S'http://bio2rdf.org/drugbank:DB00482'
p430
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CELECOXIB'
p431
sg27
Nsg28
S'Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| \r'
p432
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p433
sa(dp434
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00331'
p435
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p436
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p437
sg27
Nsg28
S'Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Metformin In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| \r'
p438
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METFORMIN'
p439
sa(dp440
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p441
sg5
S'http://bio2rdf.org/drugbank:DB00567'
p442
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CEPHALEXIN ANHYDROUS'
p443
sg27
Nsg28
S'Probenecid As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| \r'
p444
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p445
sa(dp446
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p447
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p448
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p449
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p450
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p451
sa(dp452
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01200'
p453
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p454
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p455
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p456
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BROMOCRIPTINE'
p457
sa(dp458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01219'
p459
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p460
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p461
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p462
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DANTROLENE'
p463
sa(dp464
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00052'
p465
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p466
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p467
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p468
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Somatropin'
p469
sa(dp470
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00675'
p471
sg5
S'http://bio2rdf.org/drugbank:DB00269'
p472
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLOROTRIANISENE'
p473
sg27
Nsg28
S'Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| \r'
p474
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tamoxifen'
p475
sa(dp476
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p477
sg5
S'http://bio2rdf.org/drugbank:DB00477'
p478
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLORPROMAZINE'
p479
sg27
Nsg28
S'The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| \r'
p480
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p481
sa(dp482
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p483
sg5
S'http://bio2rdf.org/drugbank:DB00672'
p484
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CHLORPROPAMIDE'
p485
sg27
Nsg28
S'Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| \r'
p486
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p487
sa(dp488
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p489
sg5
S'http://bio2rdf.org/drugbank:DB01012'
p490
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CINACALCET'
p491
sg27
Nsg28
S'Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| \r'
p492
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p493
sa(dp494
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p495
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p496
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p497
sg27
Nsg28
S'In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| \r'
p498
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p499
sa(dp500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p501
sg5
S'http://bio2rdf.org/drugbank:DB00537'
p502
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CIPROFLOXACIN'
p503
sg27
Nsg28
S'Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| \r'
p504
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p505
sa(dp506
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p507
sg5
S'http://bio2rdf.org/drugbank:DB00604'
p508
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cisapride'
p509
sg27
Nsg28
S'A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| \r'
p510
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p511
sa(dp512
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00782'
p513
sg5
S'http://bio2rdf.org/drugbank:DB01068'
p514
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLONAZEPAM'
p515
sg27
Nsg28
S'In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| \r'
p516
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROPANTHELINE'
p517
sa(dp518
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00572'
p519
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p520
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p521
sg27
Nsg28
S'Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| \r'
p522
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atropine'
p523
sa(dp524
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01228'
p525
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p526
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p527
sg27
Nsg28
S'Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| \r'
p528
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Encainide'
p529
sa(dp530
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p531
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p532
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p533
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p534
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p535
sa(dp536
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p537
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p538
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p539
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p540
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p541
sa(dp542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p543
sg5
S'http://bio2rdf.org/drugbank:DB00363'
p544
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'CLOZAPINE'
p545
sg27
Nsg28
S'However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| \r'
p546
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p547
sa(dp548
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p549
sg5
S'http://bio2rdf.org/drugbank:DB00811'
p550
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Copegus'
p551
sg27
Nsg28
S'Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| \r'
p552
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIDANOSINE'
p553
sa(dp554
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01072'
p555
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p556
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Crixivan'
p557
sg27
Nsg28
S'Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| \r'
p558
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATAZANAVIR'
p559
sa(dp560
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00705'
p561
sg5
S'http://bio2rdf.org/drugbank:DB00224'
p562
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Crixivan'
p563
sg27
Nsg28
S'Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| \r'
p564
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DELAVIRDINE'
p565
sa(dp566
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00437'
p567
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p568
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cyclophosphamide'
p569
sg27
Nsg28
S'Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| \r'
p570
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALLOPURINOL'
p571
sa(dp572
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p573
sg5
S'http://bio2rdf.org/drugbank:DB00531'
p574
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cyclophosphamide'
p575
sg27
Nsg28
S'The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| \r'
p576
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p577
sa(dp578
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00773'
p579
sg5
S'http://bio2rdf.org/drugbank:DB00091'
p580
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cyclosporin A'
p581
sg27
Nsg28
S'High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| \r'
p582
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Etoposide'
p583
sa(dp584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01234'
p585
sg5
S'http://bio2rdf.org/drugbank:DB00357'
p586
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cytadren'
p587
sg27
Nsg28
S'Cytadren accelerates the metabolism of dexamethasone;| \r'
p588
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DEXAMETHASONE'
p589
sa(dp590
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01099'
p591
sg5
S'http://bio2rdf.org/drugbank:DB00987'
p592
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Cytosine arabinoside'
p593
sg27
Nsg28
S'Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| \r'
p594
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCYTOSINE'
p595
sa(dp596
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00344'
p597
sg5
S'http://bio2rdf.org/drugbank:DB01576'
p598
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'd-amphetamine'
p599
sg27
Nsg28
S'd-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| \r'
p600
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROTRIPTYLINE'
p601
sa(dp602
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01339'
p603
sg5
S'http://bio2rdf.org/drugbank:DB01219'
p604
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DANTROLENE'
p605
sg27
Nsg28
S'Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| \r'
p606
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VECURONIUM'
p607
sa(dp608
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00205'
p609
sg5
S'http://bio2rdf.org/drugbank:DB00250'
p610
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DAPSONE'
p611
sg27
Nsg28
S'With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| \r'
p612
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PYRIMETHAMINE'
p613
sa(dp614
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00900'
p615
sg5
S'http://bio2rdf.org/drugbank:DB00705'
p616
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DELAVIRDINE'
p617
sg27
Nsg28
S'Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| \r'
p618
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Videx'
p619
sa(dp620
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00518'
p621
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p622
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p623
sg27
Nsg28
S'Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| \r'
p624
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALBENDAZOLE'
p625
sa(dp626
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p627
sg5
S'http://bio2rdf.org/drugbank:DB01234'
p628
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DEXAMETHASONE'
p629
sg27
Nsg28
S'The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| \r'
p630
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p631
sa(dp632
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p633
sg5
S'http://bio2rdf.org/drugbank:DB00405'
p634
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DEXBROMPHENIRAMINE'
p635
sg27
Nsg28
S'Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| \r'
p636
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p637
sa(dp638
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p639
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p640
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIAZEPAM'
p641
sg27
Nsg28
S'Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| \r'
p642
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p643
sa(dp644
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00580'
p645
sg5
S'http://bio2rdf.org/drugbank:DB00829'
p646
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIAZEPAM'
p647
sg27
Nsg28
S'Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| \r'
p648
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VALDECOXIB'
p649
sa(dp650
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01275'
p651
sg5
S'http://bio2rdf.org/drugbank:DB01119'
p652
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIAZOXIDE'
p653
sg27
Nsg28
S'Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| \r'
p654
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HYDRALAZINE'
p655
sa(dp656
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p657
sg5
S'http://bio2rdf.org/drugbank:DB00804'
p658
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DICYCLOMINE'
p659
sg27
Nsg28
S'Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| \r'
p660
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p661
sa(dp662
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p663
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p664
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Diflunisal'
p665
sg27
Nsg28
S'Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| \r'
p666
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p667
sa(dp668
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p669
sg5
S'http://bio2rdf.org/drugbank:DB00861'
p670
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Diflunisal'
p671
sg27
Nsg28
S'Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| \r'
p672
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p673
sa(dp674
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00640'
p675
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p676
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p677
sg27
Nsg28
S'Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| \r'
p678
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Adenocard'
p679
sa(dp680
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p681
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p682
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p683
sg27
Nsg28
S'When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| \r'
p684
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Brevibloc'
p685
sa(dp686
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00872'
p687
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p688
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p689
sg27
Nsg28
S'Digoxin Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| \r'
p690
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CONIVAPTAN'
p691
sa(dp692
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00531'
p693
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p694
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p695
sg27
Nsg28
S'Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.| \r'
p696
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cyclophosphamide'
p697
sa(dp698
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p699
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p700
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p701
sg27
Nsg28
S'In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p702
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p703
sa(dp704
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01240'
p705
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p706
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p707
sg27
Nsg28
S'However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| \r'
p708
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Flolan'
p709
sa(dp710
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p711
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p712
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIGOXIN'
p713
sg27
Nsg28
S'It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| \r'
p714
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p715
sa(dp716
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p717
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p718
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p719
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p720
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p721
sa(dp722
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p723
sg5
S'http://bio2rdf.org/drugbank:DB00320'
p724
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIHYDROERGOTAMINE'
p725
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p726
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p727
sa(dp728
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p729
sg5
S'http://bio2rdf.org/drugbank:DB01081'
p730
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DIPHENOXYLATE'
p731
sg27
Nsg28
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p732
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p733
sa(dp734
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p735
sg5
S'http://bio2rdf.org/drugbank:DB04817'
p736
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Dipyrone'
p737
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p738
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p739
sa(dp740
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p741
sg5
S'http://bio2rdf.org/drugbank:DB00757'
p742
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Dolasetron'
p743
sg27
Nsg28
S'Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| \r'
p744
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p745
sa(dp746
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00321'
p747
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p748
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p749
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p750
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMITRIPTYLINE'
p751
sa(dp752
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p753
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p754
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p755
sg27
Nsg28
S'Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| \r'
p756
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p757
sa(dp758
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00458'
p759
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p760
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p761
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p762
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IMIPRAMINE'
p763
sa(dp764
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00540'
p765
sg5
S'http://bio2rdf.org/drugbank:DB00476'
p766
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'DULOXETINE'
p767
sg27
Nsg28
S'Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| \r'
p768
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORTRIPTYLINE'
p769
sa(dp770
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p771
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p772
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Enablex'
p773
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p774
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p775
sa(dp776
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p777
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p778
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Enablex'
p779
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p780
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p781
sa(dp782
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p783
sg5
S'http://bio2rdf.org/drugbank:DB00496'
p784
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Enablex'
p785
sg27
Nsg28
S'The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| \r'
p786
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p787
sa(dp788
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01294'
p789
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p790
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXACIN'
p791
sg27
Nsg28
S'Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| \r'
p792
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BISMUTH SUBSALICYLATE'
p793
sa(dp794
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p795
sg5
S'http://bio2rdf.org/drugbank:DB00467'
p796
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXACIN'
p797
sg27
Nsg28
S'If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| \r'
p798
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p799
sa(dp800
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00261'
p801
sg5
S'http://bio2rdf.org/drugbank:DB04880'
p802
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ENOXIMONE'
p803
sg27
Nsg28
S'The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| \r'
p804
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANAGRELIDE'
p805
sa(dp806
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01170'
p807
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p808
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'EPINEPHRINE'
p809
sg27
Nsg28
S'Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| \r'
p810
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GUANETHIDINE'
p811
sa(dp812
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01064'
p813
sg5
S'http://bio2rdf.org/drugbank:DB00668'
p814
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'EPINEPHRINE'
p815
sg27
Nsg28
S'Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| \r'
p816
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Isoproterenol'
p817
sa(dp818
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p819
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p820
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ergomar'
p821
sg27
Nsg28
S'The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| \r'
p822
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Triacetyloleandomycin'
p823
sa(dp824
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00998'
p825
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p826
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERGOTAMINE'
p827
sg27
Nsg28
S'Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| \r'
p828
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Frova'
p829
sa(dp830
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00952'
p831
sg5
S'http://bio2rdf.org/drugbank:DB00696'
p832
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ERGOTAMINE'
p833
sg27
Nsg28
S'Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| \r'
p834
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NARATRIPTAN'
p835
sa(dp836
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p837
sg5
S'http://bio2rdf.org/drugbank:DB01215'
p838
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESTAZOLAM'
p839
sg27
Nsg28
S'Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| \r'
p840
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p841
sa(dp842
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p843
sg5
S'http://bio2rdf.org/drugbank:DB00402'
p844
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ESZOPICLONE'
p845
sg27
Nsg28
S'The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| \r'
p846
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p847
sa(dp848
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00260'
p849
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p850
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETHIONAMIDE'
p851
sg27
Nsg28
S'In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| \r'
p852
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CYCLOSERINE'
p853
sa(dp854
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00654'
p855
sg5
S'http://bio2rdf.org/drugbank:DB02731'
p856
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETHYLMERCURITHIOSALICYLIC ACID'
p857
sg27
Nsg28
S'In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.| \r'
p858
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LATANOPROST'
p859
sa(dp860
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p861
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p862
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Etodolac'
p863
sg27
Nsg28
S'Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| \r'
p864
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p865
sa(dp866
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p867
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p868
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p869
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p870
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Agenerase'
p871
sa(dp872
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p873
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p874
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p875
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p876
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p877
sa(dp878
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p879
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p880
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p881
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p882
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atromid-S'
p883
sa(dp884
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p885
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p886
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p887
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p888
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p889
sa(dp890
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p891
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p892
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p893
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p894
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p895
sa(dp896
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00252'
p897
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p898
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p899
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p900
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dilantin'
p901
sa(dp902
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00949'
p903
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p904
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p905
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p906
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Felbatol'
p907
sa(dp908
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p909
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p910
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p911
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p912
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fortovase'
p913
sa(dp914
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00400'
p915
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p916
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p917
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p918
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gris-PEG'
p919
sa(dp920
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01232'
p921
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p922
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p923
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p924
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Invirase'
p925
sa(dp926
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p927
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p928
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p929
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p930
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Kadian'
p931
sa(dp932
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01076'
p933
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p934
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p935
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p936
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Lipitor'
p937
sa(dp938
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00295'
p939
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p940
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p941
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p942
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MS Contin'
p943
sa(dp944
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p945
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p946
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p947
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p948
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Neoral '
p949
sa(dp950
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p951
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p952
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p953
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p954
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nizoral'
p955
sa(dp956
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p957
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p958
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p959
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p960
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Norvir'
p961
sa(dp962
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p963
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p964
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p965
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p966
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p967
sa(dp968
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00812'
p969
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p970
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p971
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p972
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENYLBUTAZONE'
p973
sa(dp974
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00860'
p975
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p976
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p977
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p978
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Prelone'
p979
sa(dp980
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p981
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p982
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p983
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p984
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifadin'
p985
sa(dp986
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01045'
p987
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p988
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p989
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p990
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Rifampin'
p991
sa(dp992
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00091'
p993
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p994
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p995
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p996
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sandimmune '
p997
sa(dp998
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p999
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p1000
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p1001
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p1002
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sporanox'
p1003
sa(dp1004
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p1005
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p1006
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p1007
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p1008
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TEGretol'
p1009
sa(dp1010
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00277'
p1011
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p1012
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p1013
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p1014
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Theo-Dur'
p1015
sa(dp1016
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00273'
p1017
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p1018
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p1019
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p1020
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Topamax'
p1021
sa(dp1022
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00776'
p1023
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p1024
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p1025
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p1026
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Trileptal'
p1027
sa(dp1028
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00316'
p1029
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p1030
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p1031
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p1032
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tylenol'
p1033
sa(dp1034
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p1035
sg5
S'http://bio2rdf.org/drugbank:DB00294'
p1036
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ETONOGESTREL'
p1037
sg27
Nsg28
S'Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| \r'
p1038
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Viracept'
p1039
sa(dp1040
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1041
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p1042
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fentanyl'
p1043
sg27
Nsg28
S'Central Nervous System Depressants The concomitant use of DURAGESIC? (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| \r'
p1044
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1045
sa(dp1046
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1047
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p1048
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fentanyl'
p1049
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p1050
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1051
sa(dp1052
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00220'
p1053
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p1054
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fentanyl'
p1055
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p1056
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NELFINAVIR'
p1057
sa(dp1058
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p1059
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p1060
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fentanyl'
p1061
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p1062
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p1063
sa(dp1064
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01361'
p1065
sg5
S'http://bio2rdf.org/drugbank:DB00813'
p1066
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fentanyl'
p1067
sg27
Nsg28
S'The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| \r'
p1068
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TROLEANDOMYCIN'
p1069
sa(dp1070
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1071
sg5
S'http://bio2rdf.org/drugbank:DB00924'
p1072
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Flexeril'
p1073
sg27
Nsg28
S'FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| \r'
p1074
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1075
sa(dp1076
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p1077
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1078
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p1079
sg27
Nsg28
S'Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| \r'
p1080
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CELECOXIB'
p1081
sa(dp1082
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1083
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1084
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p1085
sg27
Nsg28
S'Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p1086
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1087
sa(dp1088
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1089
sg5
S'http://bio2rdf.org/drugbank:DB00196'
p1090
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUCONAZOLE'
p1091
sg27
Nsg28
S'Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p1092
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1093
sa(dp1094
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00552'
p1095
sg5
S'http://bio2rdf.org/drugbank:DB01073'
p1096
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fludara'
p1097
sg27
Nsg28
S'The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| \r'
p1098
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENTOSTATIN'
p1099
sa(dp1100
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01199'
p1101
sg5
S'http://bio2rdf.org/drugbank:DB01159'
p1102
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Fluothane'
p1103
sg27
Nsg28
S'FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| \r'
p1104
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TUBOCURARINE'
p1105
sa(dp1106
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p1107
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p1108
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p1109
sg27
Nsg28
S'Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;| Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| \r'
p1110
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p1111
sa(dp1112
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p1113
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p1114
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p1115
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p1116
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p1117
sa(dp1118
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1119
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p1120
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p1121
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p1122
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1123
sa(dp1124
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p1125
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p1126
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p1127
sg27
Nsg28
S'Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| \r'
p1128
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p1129
sa(dp1130
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00857'
p1131
sg5
S'http://bio2rdf.org/drugbank:DB00176'
p1132
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'FLUVOXAMINE'
p1133
sg27
Nsg28
S'Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| \r'
p1134
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TERBINAFINE'
p1135
sa(dp1136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p1137
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p1138
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Foscavir'
p1139
sg27
Nsg28
S'Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| \r'
p1140
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p1141
sa(dp1142
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p1143
sg5
S'http://bio2rdf.org/drugbank:DB00529'
p1144
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Foscavir'
p1145
sg27
Nsg28
S'A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| \r'
p1146
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pentamidin'
p1147
sa(dp1148
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p1149
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p1150
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GEMFIBROZIL'
p1151
sg27
Nsg28
S'Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p1152
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p1153
sa(dp1154
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p1155
sg5
S'http://bio2rdf.org/drugbank:DB01241'
p1156
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GEMFIBROZIL'
p1157
sg27
Nsg28
S'Concomitant administration of gemfibrozil with Targretin ? capsules is not recommended.| \r'
p1158
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Targretin'
p1159
sa(dp1160
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1161
sg5
S'http://bio2rdf.org/drugbank:DB00619'
p1162
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Gleevec'
p1163
sg27
Nsg28
S'Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| \r'
p1164
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1165
sa(dp1166
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p1167
sg5
S'http://bio2rdf.org/drugbank:DB01067'
p1168
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GLIPIZIDE'
p1169
sg27
Nsg28
S'The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| \r'
p1170
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p1171
sa(dp1172
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p1173
sg5
S'http://bio2rdf.org/drugbank:DB01170'
p1174
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GUANETHIDINE'
p1175
sg27
Nsg28
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p1176
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p1177
sa(dp1178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p1179
sg5
S'http://bio2rdf.org/drugbank:DB01018'
p1180
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'GUANFACINE'
p1181
sg27
Nsg28
S'The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| \r'
p1182
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p1183
sa(dp1184
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p1185
sg5
S'http://bio2rdf.org/drugbank:DB00999'
p1186
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'HCTZ'
p1187
sg27
Nsg28
S'Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.| In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and Cmax by 16%.| \r'
p1188
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAMTERENE'
p1189
sa(dp1190
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00404'
p1191
sg5
S'http://bio2rdf.org/drugbank:DB00458'
p1192
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'IMIPRAMINE'
p1193
sg27
Nsg28
S'The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| \r'
p1194
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALPRAZOLAM'
p1195
sa(dp1196
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00503'
p1197
sg5
S'http://bio2rdf.org/drugbank:DB01232'
p1198
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Invirase'
p1199
sg27
Nsg28
S'Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| \r'
p1200
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'RITONAVIR'
p1201
sa(dp1202
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p1203
sg5
S'http://bio2rdf.org/drugbank:DB01029'
p1204
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Irbesartan'
p1205
sg27
Nsg28
S'Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| \r'
p1206
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p1207
sa(dp1208
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00565'
p1209
sg5
S'http://bio2rdf.org/drugbank:DB00753'
p1210
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Isoflurane'
p1211
sg27
Nsg28
S'In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| \r'
p1212
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nimbex'
p1213
sa(dp1214
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1215
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p1216
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p1217
sg27
Nsg28
S'INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| \r'
p1218
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1219
sa(dp1220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p1221
sg5
S'http://bio2rdf.org/drugbank:DB00951'
p1222
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ISONIAZID'
p1223
sg27
Nsg28
S'Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| \r'
p1224
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p1225
sa(dp1226
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01258'
p1227
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1228
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1229
sg27
Nsg28
S'Ketoconazole Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| \r'
p1230
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALISKIREN'
p1231
sa(dp1232
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p1233
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1234
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1235
sg27
Nsg28
S'10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| \r'
p1236
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p1237
sa(dp1238
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01238'
p1239
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1240
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1241
sg27
Nsg28
S'Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| \r'
p1242
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ARIPIPRAZOLE'
p1243
sa(dp1244
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00637'
p1245
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1246
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1247
sg27
Nsg28
S'Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| \r'
p1248
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ASTEMIZOLE'
p1249
sa(dp1250
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p1251
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1252
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1253
sg27
Nsg28
S'On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| \r'
p1254
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p1255
sa(dp1256
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1257
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1258
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1259
sg27
Nsg28
S'Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| \r'
p1260
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1261
sa(dp1262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p1263
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1264
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1265
sg27
Nsg28
S'Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| When Ketoconazole is given in combination with isoniazid and rifampin the AUC of ketoconazole is decreased by as much as 88% after 5 months of concurrent Isoniazid and Rifampin therapy.| \r'
p1266
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p1267
sa(dp1268
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00959'
p1269
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1270
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1271
sg27
Nsg28
S'Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| \r'
p1272
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METHYLPREDNISOLONE'
p1273
sa(dp1274
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01012'
p1275
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1276
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1277
sg27
Nsg28
S'Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| \r'
p1278
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Sensipar'
p1279
sa(dp1280
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1281
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1282
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1283
sg27
Nsg28
S'Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| \r'
p1284
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p1285
sa(dp1286
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p1287
sg5
S'http://bio2rdf.org/drugbank:DB01026'
p1288
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ketoconazole'
p1289
sg27
Nsg28
S'Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| \r'
p1290
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p1291
sa(dp1292
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00943'
p1293
sg5
S'http://bio2rdf.org/drugbank:DB00709'
p1294
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lamivudine'
p1295
sg27
Nsg28
S'Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| \r'
p1296
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALCITABINE'
p1297
sa(dp1298
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p1299
sg5
S'http://bio2rdf.org/drugbank:DB00448'
p1300
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lansoprazole'
p1301
sg27
Nsg28
S'therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| \r'
p1302
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p1303
sa(dp1304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1305
sg5
S'http://bio2rdf.org/drugbank:DB00854'
p1306
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Levo-Dromoran'
p1307
sg27
Nsg28
S'Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| \r'
p1308
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1309
sa(dp1310
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p1311
sg5
S'http://bio2rdf.org/drugbank:DB00424'
p1312
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Levsin'
p1313
sg27
Nsg28
S'Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| \r'
p1314
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p1315
sa(dp1316
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1317
sg5
S'http://bio2rdf.org/drugbank:DB01175'
p1318
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lexapro'
p1319
sg27
Nsg28
S'Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| \r'
p1320
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1321
sa(dp1322
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1323
sg5
S'http://bio2rdf.org/drugbank:DB00749'
p1324
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Lodine'
p1325
sg27
Nsg28
S'Aspirin When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p1326
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1327
sa(dp1328
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00454'
p1329
sg5
S'http://bio2rdf.org/drugbank:DB00454'
p1330
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MEPERIDINE'
p1331
sg27
Nsg28
S'Meperidine - Amphetamines pone the analgesic effect of meperidine.| \r'
p1332
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEPERIDINE'
p1333
sa(dp1334
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1335
sg5
S'http://bio2rdf.org/drugbank:DB00331'
p1336
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METFORMIN'
p1337
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p1338
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p1339
sa(dp1340
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p1341
sg5
S'http://bio2rdf.org/drugbank:DB00959'
p1342
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METHYLPREDNISOLONE'
p1343
sg27
Nsg28
S'The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| \r'
p1344
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p1345
sa(dp1346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00714'
p1347
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p1348
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p1349
sg27
Nsg28
S'Dopamine Antagonists Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenoth-iazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| \r'
p1350
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Apokyn'
p1351
sa(dp1352
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1353
sg5
S'http://bio2rdf.org/drugbank:DB01233'
p1354
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'METOCLOPRAMIDE'
p1355
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p1356
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1357
sa(dp1358
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00673'
p1359
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p1360
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MIDAZOLAM'
p1361
sg27
Nsg28
S'The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| \r'
p1362
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'APREPITANT'
p1363
sa(dp1364
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1365
sg5
S'http://bio2rdf.org/drugbank:DB00683'
p1366
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MIDAZOLAM'
p1367
sg27
Nsg28
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p1368
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p1369
sa(dp1370
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00918'
p1371
sg5
S'http://bio2rdf.org/drugbank:DB01171'
p1372
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'MOCLOBEMIDE'
p1373
sg27
Nsg28
S'Monoamine Oxidase Inhibitors Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| \r'
p1374
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ALMOTRIPTAN'
p1375
sa(dp1376
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00828'
p1377
sg5
S'http://bio2rdf.org/drugbank:DB00828'
p1378
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Monurol'
p1379
sg27
Nsg28
S'Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| \r'
p1380
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOSFOMYCIN'
p1381
sa(dp1382
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00898'
p1383
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p1384
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Nabilone'
p1385
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| \r'
p1386
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Alcohol'
p1387
sa(dp1388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p1389
sg5
S'http://bio2rdf.org/drugbank:DB00486'
p1390
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Nabilone'
p1391
sg27
Nsg28
S'Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| \r'
p1392
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p1393
sa(dp1394
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00659'
p1395
sg5
S'http://bio2rdf.org/drugbank:DB00704'
p1396
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NALTREXONE'
p1397
sg27
Nsg28
S'Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| \r'
p1398
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACAMPROSATE'
p1399
sa(dp1400
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1401
sg5
S'http://bio2rdf.org/drugbank:DB00788'
p1402
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NAPROXEN'
p1403
sg27
Nsg28
S'Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| \r'
p1404
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1405
sa(dp1406
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1407
sg5
S'http://bio2rdf.org/drugbank:DB01149'
p1408
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NEFAZODONE'
p1409
sg27
Nsg28
S'Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p1410
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1411
sa(dp1412
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00701'
p1413
sg5
S'http://bio2rdf.org/drugbank:DB00220'
p1414
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NELFINAVIR'
p1415
sg27
Nsg28
S'Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| \r'
p1416
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPRENAVIR'
p1417
sa(dp1418
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p1419
sg5
S'http://bio2rdf.org/drugbank:DB00565'
p1420
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Nimbex'
p1421
sg27
Nsg28
S'Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced ?95% neuromuscular block.| \r'
p1422
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p1423
sa(dp1424
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00435'
p1425
sg5
S'http://bio2rdf.org/drugbank:DB00727'
p1426
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NITROGLYCERIN'
p1427
sg27
Nsg28
S'Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| \r'
p1428
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INOmax'
p1429
sa(dp1430
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00996'
p1431
sg5
S'http://bio2rdf.org/drugbank:DB00717'
p1432
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NORETHINDRONE'
p1433
sg27
Nsg28
S'The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| \r'
p1434
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GABAPENTIN'
p1435
sa(dp1436
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1437
sg5
S'http://bio2rdf.org/drugbank:DB01059'
p1438
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'NORFLOXACIN'
p1439
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p1440
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p1441
sa(dp1442
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1443
sg5
S'http://bio2rdf.org/drugbank:DB03585'
p1444
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Oxyphenbutazone'
p1445
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p1446
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1447
sa(dp1448
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00289'
p1449
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p1450
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p1451
sg27
Nsg28
S'In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| \r'
p1452
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ATOMOXETINE'
p1453
sa(dp1454
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00363'
p1455
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p1456
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p1457
sg27
Nsg28
S'Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| \r'
p1458
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOZAPINE'
p1459
sa(dp1460
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00476'
p1461
sg5
S'http://bio2rdf.org/drugbank:DB00715'
p1462
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PAROXETINE'
p1463
sg27
Nsg28
S'Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| \r'
p1464
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DULOXETINE'
p1465
sa(dp1466
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p1467
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p1468
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Peganone'
p1469
sg27
Nsg28
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p1470
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENACEMIDE'
p1471
sa(dp1472
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01121'
p1473
sg5
S'http://bio2rdf.org/drugbank:DB00754'
p1474
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Peganone'
p1475
sg27
Nsg28
S'Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| \r'
p1476
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Phenurone'
p1477
sa(dp1478
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00854'
p1479
sg5
S'http://bio2rdf.org/drugbank:DB00652'
p1480
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Pentazocine'
p1481
sg27
Nsg28
S'Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| \r'
p1482
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Levo-Dromoran'
p1483
sa(dp1484
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1485
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p1486
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p1487
sg27
Nsg28
S'Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| \r'
p1488
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1489
sa(dp1490
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p1491
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p1492
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p1493
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p1494
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p1495
sa(dp1496
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00136'
p1497
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p1498
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p1499
sg27
Nsg28
S'Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| \r'
p1500
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CALCITRIOL'
p1501
sa(dp1502
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01068'
p1503
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p1504
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p1505
sg27
Nsg28
S'Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| \r'
p1506
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONAZEPAM'
p1507
sa(dp1508
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00990'
p1509
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p1510
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p1511
sg27
Nsg28
S'Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| \r'
p1512
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'EXEMESTANE'
p1513
sa(dp1514
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p1515
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p1516
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p1517
sg27
Nsg28
S'Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| \r'
p1518
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Fenoprofen'
p1519
sa(dp1520
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p1521
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p1522
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p1523
sg27
Nsg28
S'When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| \r'
p1524
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Nalfon'
p1525
sa(dp1526
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p1527
sg5
S'http://bio2rdf.org/drugbank:DB01174'
p1528
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENOBARBITAL'
p1529
sg27
Nsg28
S'Phenobarbital - Amphetamines may delay intestinal absorption of phenobarbital;| \r'
p1530
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p1531
sa(dp1532
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1533
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p1534
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYLBUTAZONE'
p1535
sg27
Nsg28
S'Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| \r'
p1536
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1537
sa(dp1538
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00749'
p1539
sg5
S'http://bio2rdf.org/drugbank:DB00812'
p1540
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PHENYLBUTAZONE'
p1541
sg27
Nsg28
S'Phenylbutazone Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| \r'
p1542
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Etodolac'
p1543
sa(dp1544
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00202'
p1545
sg5
S'http://bio2rdf.org/drugbank:DB01057'
p1546
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Phospholine Iodide'
p1547
sg27
Nsg28
S'Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| \r'
p1548
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SUCCINYLCHOLINE'
p1549
sa(dp1550
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1551
sg5
S'http://bio2rdf.org/drugbank:DB01166'
p1552
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Pletal'
p1553
sg27
Nsg28
S'Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| \r'
p1554
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1555
sa(dp1556
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00945'
p1557
sg5
S'http://bio2rdf.org/drugbank:DB00784'
p1558
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Ponstel'
p1559
sg27
Nsg28
S'Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| \r'
p1560
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Aspirin'
p1561
sa(dp1562
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00384'
p1563
sg5
S'http://bio2rdf.org/drugbank:DB00722'
p1564
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Prinivil'
p1565
sg27
Nsg28
S'Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| \r'
p1566
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAMTERENE'
p1567
sa(dp1568
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00787'
p1569
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1570
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1571
sg27
Nsg28
S'Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p1572
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACYCLOVIR'
p1573
sa(dp1574
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00233'
p1575
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1576
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1577
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p1578
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMINOSALICYLIC ACID'
p1579
sa(dp1580
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00415'
p1581
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1582
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1583
sg27
Nsg28
S'Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| \r'
p1584
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPICILLIN'
p1585
sa(dp1586
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00887'
p1587
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1588
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1589
sg27
Nsg28
S'- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| This antagonistic effect of probenecid on bu-metanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| \r'
p1590
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Bumetanide'
p1591
sa(dp1592
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00535'
p1593
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1594
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1595
sg27
Nsg28
S'Probenecid As with other b span class= c233 -lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| \r'
p1596
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CEFDINIR'
p1597
sa(dp1598
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p1599
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1600
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1601
sg27
Nsg28
S'Probenecid Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| \r'
p1602
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p1603
sa(dp1604
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p1605
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1606
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1607
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p1608
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLOFIBRATE'
p1609
sa(dp1610
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00927'
p1611
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1612
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1613
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p1614
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FAMOTIDINE'
p1615
sa(dp1616
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p1617
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1618
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1619
sg27
Nsg28
S'Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| \r'
p1620
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p1621
sa(dp1622
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p1623
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1624
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1625
sg27
Nsg28
S'Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| \r'
p1626
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p1627
sa(dp1628
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00299'
p1629
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1630
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1631
sg27
Nsg28
S'Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| \r'
p1632
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PENCICLOVIR'
p1633
sa(dp1634
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p1635
sg5
S'http://bio2rdf.org/drugbank:DB01032'
p1636
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROBENECID'
p1637
sg27
Nsg28
S'Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| \r'
p1638
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p1639
sa(dp1640
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1641
sg5
S'http://bio2rdf.org/drugbank:DB00782'
p1642
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PROPANTHELINE'
p1643
sg27
Nsg28
S'Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| \r'
p1644
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1645
sa(dp1646
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00488'
p1647
sg5
S'http://bio2rdf.org/drugbank:DB00165'
p1648
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'PYRIDOXINE'
p1649
sg27
Nsg28
S'however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| \r'
p1650
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Hexalen'
p1651
sa(dp1652
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1653
sg5
S'http://bio2rdf.org/drugbank:DB00468'
p1654
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'QUININE'
p1655
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p1656
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p1657
sa(dp1658
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p1659
sg5
S'http://bio2rdf.org/drugbank:DB00206'
p1660
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RESERPINE'
p1661
sg27
Nsg28
S'Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| \r'
p1662
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p1663
sa(dp1664
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00459'
p1665
sg5
S'http://bio2rdf.org/drugbank:DB00162'
p1666
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RETINOL'
p1667
sg27
Nsg28
S'Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| \r'
p1668
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ACITRETIN'
p1669
sa(dp1670
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00224'
p1671
sg5
S'http://bio2rdf.org/drugbank:DB00615'
p1672
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RIFABUTIN'
p1673
sg27
Nsg28
S'Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| \r'
p1674
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Crixivan'
p1675
sa(dp1676
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p1677
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p1678
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampin'
p1679
sg27
Nsg28
S'Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| \r'
p1680
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p1681
sa(dp1682
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1683
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p1684
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampin'
p1685
sg27
Nsg28
S'Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| \r'
p1686
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1687
sa(dp1688
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01215'
p1689
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p1690
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampin'
p1691
sg27
Nsg28
S'While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| \r'
p1692
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESTAZOLAM'
p1693
sa(dp1694
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00619'
p1695
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p1696
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampin'
p1697
sg27
Nsg28
S'Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| \r'
p1698
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Gleevec'
p1699
sa(dp1700
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00502'
p1701
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p1702
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampin'
p1703
sg27
Nsg28
S'Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| \r'
p1704
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'HALOPERIDOL'
p1705
sa(dp1706
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1707
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p1708
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampin'
p1709
sg27
Nsg28
S'Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| \r'
p1710
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1711
sa(dp1712
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00612'
p1713
sg5
S'http://bio2rdf.org/drugbank:DB01045'
p1714
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Rifampin'
p1715
sg27
Nsg28
S'Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| \r'
p1716
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Zebeta'
p1717
sa(dp1718
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1719
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p1720
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RITONAVIR'
p1721
sg27
Nsg28
S'Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p1722
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1723
sa(dp1724
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00529'
p1725
sg5
S'http://bio2rdf.org/drugbank:DB00503'
p1726
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'RITONAVIR'
p1727
sg27
Nsg28
S'Abnormal renal function has been observed in clinical practice during the use of FASCAVIR and ritonavir, or FOSCAVIR, ritonavir, and saquinavir.| \r'
p1728
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Foscavir'
p1729
sa(dp1730
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00761'
p1731
sg5
S'http://bio2rdf.org/drugbank:DB00986'
p1732
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Robinul'
p1733
sg27
Nsg28
S'Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| \r'
p1734
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POTASSIUM CHLORIDE'
p1735
sa(dp1736
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00962'
p1737
sg5
S'http://bio2rdf.org/drugbank:DB00962'
p1738
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Sonata'
p1739
sg27
Nsg28
S'Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.| \r'
p1740
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZALEPLON'
p1741
sa(dp1742
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1743
sg5
S'http://bio2rdf.org/drugbank:DB00421'
p1744
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Spironolactone'
p1745
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p1746
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1747
sa(dp1748
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00187'
p1749
sg5
S'http://bio2rdf.org/drugbank:DB00202'
p1750
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUCCINYLCHOLINE'
p1751
sg27
Nsg28
S'The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| \r'
p1752
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Brevibloc'
p1753
sa(dp1754
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1755
sg5
S'http://bio2rdf.org/drugbank:DB00795'
p1756
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SULFASALAZINE'
p1757
sg27
Nsg28
S'Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| \r'
p1758
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1759
sa(dp1760
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01175'
p1761
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p1762
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p1763
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p1764
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ESCITALOPRAM'
p1765
sa(dp1766
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1767
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p1768
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p1769
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p1770
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p1771
sa(dp1772
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p1773
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p1774
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p1775
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p1776
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p1777
sa(dp1778
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01104'
p1779
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p1780
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p1781
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p1782
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p1783
sa(dp1784
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB08567'
p1785
sg5
S'http://bio2rdf.org/drugbank:DB00669'
p1786
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'SUMATRIPTAN'
p1787
sg27
Nsg28
S'If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| \r'
p1788
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SERTRALINE'
p1789
sa(dp1790
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00475'
p1791
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1792
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p1793
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p1794
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CHLORDIAZEPOXIDE'
p1795
sa(dp1796
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00829'
p1797
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1798
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p1799
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p1800
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIAZEPAM'
p1801
sa(dp1802
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00916'
p1803
sg5
S'http://bio2rdf.org/drugbank:DB00501'
p1804
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tagamet'
p1805
sg27
Nsg28
S'Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| \r'
p1806
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METRONIDAZOLE'
p1807
sa(dp1808
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1809
sg5
S'http://bio2rdf.org/drugbank:DB01195'
p1810
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tambocor'
p1811
sg27
Nsg28
S'During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| \r'
p1812
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1813
sa(dp1814
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01217'
p1815
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p1816
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tamoxifen'
p1817
sg27
Nsg28
S'Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY ? Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| \r'
p1818
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ANASTROZOLE'
p1819
sa(dp1820
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00307'
p1821
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p1822
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Targretin'
p1823
sg27
Nsg28
S'Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p1824
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BEXAROTENE'
p1825
sa(dp1826
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p1827
sg5
S'http://bio2rdf.org/drugbank:DB00307'
p1828
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Targretin'
p1829
sg27
Nsg28
S'Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| \r'
p1830
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEMFIBROZIL'
p1831
sa(dp1832
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01174'
p1833
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p1834
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIAGABINE'
p1835
sg27
Nsg28
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p1836
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PHENOBARBITAL'
p1837
sa(dp1838
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00794'
p1839
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p1840
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIAGABINE'
p1841
sg27
Nsg28
S'Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| \r'
p1842
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PRIMIDONE'
p1843
sa(dp1844
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00313'
p1845
sg5
S'http://bio2rdf.org/drugbank:DB00906'
p1846
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TIAGABINE'
p1847
sg27
Nsg28
S'Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| \r'
p1848
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Valproate'
p1849
sa(dp1850
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p1851
sg5
S'http://bio2rdf.org/drugbank:DB00204'
p1852
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Tikosyn'
p1853
sg27
Nsg28
S'Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| \r'
p1854
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p1855
sa(dp1856
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00636'
p1857
sg5
S'http://bio2rdf.org/drugbank:DB01124'
p1858
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TOLBUTAMIDE'
p1859
sg27
Nsg28
S'The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| \r'
p1860
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Atromid-S'
p1861
sa(dp1862
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p1863
sg5
S'http://bio2rdf.org/drugbank:DB00609'
p1864
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Trecator'
p1865
sg27
Nsg28
S'Trecator has been found to temporarily raise serum concentrations of isoniazid.| \r'
p1866
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p1867
sa(dp1868
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1869
sg5
S'http://bio2rdf.org/drugbank:DB00384'
p1870
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAMTERENE'
p1871
sg27
Nsg28
S'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| \r'
p1872
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p1873
sa(dp1874
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00176'
p1875
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p1876
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAZOLAM'
p1877
sg27
Nsg28
S'Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| \r'
p1878
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVOXAMINE'
p1879
sa(dp1880
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00897'
p1881
sg5
S'http://bio2rdf.org/drugbank:DB00897'
p1882
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIAZOLAM'
p1883
sg27
Nsg28
S'Triazolam Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| \r'
p1884
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TRIAZOLAM'
p1885
sa(dp1886
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01015'
p1887
sg5
S'http://bio2rdf.org/drugbank:DB00440'
p1888
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TRIMETHOPRIM'
p1889
sg27
Nsg28
S'Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.| \r'
p1890
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAMETHOXAZOLE'
p1891
sa(dp1892
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00604'
p1893
sg5
S'http://bio2rdf.org/drugbank:DB01361'
p1894
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'TROLEANDOMYCIN'
p1895
sg27
Nsg28
S'Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| \r'
p1896
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cisapride'
p1897
sa(dp1898
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00514'
p1899
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p1900
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p1901
sg27
Nsg28
S'Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| \r'
p1902
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Dextromethorphan'
p1903
sa(dp1904
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p1905
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p1906
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p1907
sg27
Nsg28
S'Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p1908
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p1909
sa(dp1910
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p1911
sg5
S'http://bio2rdf.org/drugbank:DB00580'
p1912
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'VALDECOXIB'
p1913
sg27
Nsg28
S'Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| \r'
p1914
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Ketoconazole'
p1915
sa(dp1916
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00951'
p1917
sg5
S'http://bio2rdf.org/drugbank:DB00313'
p1918
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Valproate'
p1919
sg27
Nsg28
S'Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| \r'
p1920
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ISONIAZID'
p1921
sa(dp1922
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00390'
p1923
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p1924
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p1925
sg27
Nsg28
S'Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| \r'
p1926
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIGOXIN'
p1927
sa(dp1928
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p1929
sg5
S'http://bio2rdf.org/drugbank:DB00661'
p1930
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Verapamil'
p1931
sg27
Nsg28
S'In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| \r'
p1932
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DOFETILIDE'
p1933
sa(dp1934
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p1935
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p1936
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Videx'
p1937
sg27
Nsg28
S'Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| \r'
p1938
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p1939
sa(dp1940
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p1941
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p1942
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Videx'
p1943
sg27
Nsg28
S'Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| \r'
p1944
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Factive'
p1945
sa(dp1946
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01004'
p1947
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p1948
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Videx'
p1949
sg27
Nsg28
S'A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| \r'
p1950
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GANCICLOVIR'
p1951
sa(dp1952
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01059'
p1953
sg5
S'http://bio2rdf.org/drugbank:DB00900'
p1954
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Videx'
p1955
sg27
Nsg28
S'Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| \r'
p1956
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NORFLOXACIN'
p1957
sa(dp1958
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00479'
p1959
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p1960
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p1961
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p1962
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Amikacin'
p1963
sa(dp1964
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00681'
p1965
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p1966
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p1967
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p1968
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMPHOTERICIN B'
p1969
sa(dp1970
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00529'
p1971
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p1972
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p1973
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p1974
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FOSCARNET'
p1975
sa(dp1976
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00738'
p1977
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p1978
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p1979
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p1980
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Pentamidin'
p1981
sa(dp1982
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00684'
p1983
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p1984
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p1985
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p1986
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOBRAMYCIN'
p1987
sa(dp1988
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00512'
p1989
sg5
S'http://bio2rdf.org/drugbank:DB00369'
p1990
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Vistide'
p1991
sg27
Nsg28
S'Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| \r'
p1992
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VANCOMYCIN'
p1993
sa(dp1994
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00531'
p1995
sg5
S'http://bio2rdf.org/drugbank:DB01156'
p1996
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Wellbutrin'
p1997
sg27
Nsg28
S'Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| \r'
p1998
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Cyclophosphamide'
p1999
sa(dp2000
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00204'
p2001
sg5
S'http://bio2rdf.org/drugbank:DB00549'
p2002
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZAFIRLUKAST'
p2003
sg27
Nsg28
S'Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| \r'
p2004
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Tikosyn'
p2005
sa(dp2006
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00575'
p2007
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p2008
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Zebeta'
p2009
sg27
Nsg28
S'In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| \r'
p2010
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLONIDINE'
p2011
sa(dp2012
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00661'
p2013
sg5
S'http://bio2rdf.org/drugbank:DB00612'
p2014
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'Zebeta'
p2015
sg27
Nsg28
S'ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| \r'
p2016
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'Verapamil'
p2017
sa(dp2018
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01032'
p2019
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p2020
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p2021
sg27
Nsg28
S'Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| \r'
p2022
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PROBENECID'
p2023
sa(dp2024
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00649'
p2025
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p2026
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p2027
sg27
Nsg28
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p2028
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'STAVUDINE'
p2029
sa(dp2030
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00495'
p2031
sg5
S'http://bio2rdf.org/drugbank:DB00495'
p2032
sg7
Nsg8
Nsg9
Nsg10
Nsg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
g17
sg18
Nsg19
Nsg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
S'ZIDOVUDINE'
p2033
sg27
Nsg28
S'Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| \r'
p2034
sg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ZIDOVUDINE'
p2035
sa.